Absorbable biomedical materials producer Haohai Healthcare has supplied $14m of series A capital for Recros Medica, the US-based developer of a fractional plastic surgery technique.
Founded in 2014, Recros Medica has developed a minimally-invasive plastic surgery operation that relies on a technique called rotational fractional resectioning to improve the smoothness of skin.
Proceeds from the round will progress the product under the brand name of Nuvellus Focal Contouring System, and fund a clinical study to support regulatory approval in the US. Haohai has also gained an option to acquire Chinese marketing rights for the technology.
Recros Medica raised $9m from investment firm Longwood Fund in January 2018, after securing $4.4m in financing in mid-2017 and $250,000 in equity funding three years earlier, according to regulatory filings.